首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   35004篇
  免费   3826篇
  国内免费   39篇
耳鼻咽喉   217篇
儿科学   1143篇
妇产科学   973篇
基础医学   4873篇
口腔科学   707篇
临床医学   4259篇
内科学   6337篇
皮肤病学   572篇
神经病学   3050篇
特种医学   1479篇
外国民族医学   3篇
外科学   4566篇
综合类   801篇
现状与发展   20篇
一般理论   43篇
预防医学   4245篇
眼科学   904篇
药学   2594篇
中国医学   47篇
肿瘤学   2036篇
  2021年   624篇
  2020年   348篇
  2019年   581篇
  2018年   646篇
  2017年   506篇
  2016年   541篇
  2015年   582篇
  2014年   797篇
  2013年   1186篇
  2012年   1645篇
  2011年   1620篇
  2010年   979篇
  2009年   896篇
  2008年   1476篇
  2007年   1550篇
  2006年   1552篇
  2005年   1475篇
  2004年   1440篇
  2003年   1351篇
  2002年   1283篇
  2001年   1203篇
  2000年   1212篇
  1999年   1045篇
  1998年   446篇
  1997年   407篇
  1996年   395篇
  1995年   326篇
  1994年   345篇
  1993年   338篇
  1992年   820篇
  1991年   787篇
  1990年   777篇
  1989年   678篇
  1988年   704篇
  1987年   655篇
  1986年   605篇
  1985年   668篇
  1984年   535篇
  1983年   421篇
  1982年   271篇
  1981年   278篇
  1980年   255篇
  1979年   461篇
  1978年   352篇
  1977年   263篇
  1976年   276篇
  1975年   256篇
  1974年   285篇
  1973年   261篇
  1972年   269篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
Erosive pustular dermatosis of the scalp (EPDS) is an uncommon chronic inflammatory response to scalp trauma that usually resolves with cicatricial alopecia. It most commonly affects elderly patients with a history of actinic damage. Herein, we describe a 16‐year‐old girl with acrofacial dysostosis type 1 presenting after surgery with crusting purulent scalp lesions, whose clinical presentation and histopathologic findings were consistent with EPDS. A review of the literature on EPDS in children is also detailed.  相似文献   
3.
4.
5.
6.
Background Immune checkpoint blockers (ICBs) activate CD8+ T cells, eliciting both anti-cancer activity and immune-related adverse events (irAEs). The relationship of irAEs with baseline parameters and clinical outcome is unclear.Methods Retrospective evaluation of irAEs on survival was performed across primary (N = 144) and secondary (N = 211) independent cohorts of patients with metastatic melanoma receiving single agent (pembrolizumab/nivolumab—sICB) or combination (nivolumab and ipilimumab—cICB) checkpoint blockade. RNA from pre-treatment and post-treatment CD8+ T cells was sequenced and differential gene expression according to irAE development assessed.Results 58.3% of patients developed early irAEs and this was associated with longer progression-free (PFS) and overall survival (OS) across both cohorts (log-rank test, OS: P < 0.0001). Median survival for patients without irAEs was 16.6 months (95% CI: 10.9–33.4) versus not-reached (P = 2.8 × 10−6). Pre-treatment monocyte and neutrophil counts, but not BMI, were additional predictors of clinical outcome. Differential expression of numerous gene pathway members was observed in CD8+ T cells according to irAE development, and patients not developing irAEs demonstrating upregulated CXCR1 pre- and post-treatment.Conclusions Early irAE development post-ICB is associated with favourable survival in MM. Development of irAEs is coupled to expression of numerous gene pathways, suggesting irAE development in-part reflects baseline immune activation.Subject terms: Immunotherapy, Melanoma  相似文献   
7.
Contrast‐enhanced spectral mammography (CESM) has a number of uses including the work‐up of inconclusive findings on mammography, assessment of breast symptoms, cancer staging, evaluation of response to neoadjuvant chemotherapy and recently as an alternative to magnetic resonance imaging (MRI) in high‐risk screening. CESM can be swiftly incorporated into the workflow of busy breast clinics. We share our experiences with CESM at a large breast assessment centre in Western Australia.  相似文献   
8.
9.

Introduction/Hypothesis

Recruitment of participants into phase 1 vaccine clinical trials can be challenging since these vaccines have not been used in humans and there is no perceived benefit to the participant. Occasionally, as was the case with a phase 1 clinical trial of an Ebola vaccine in Halifax, Canada, during the 2014–2016 West African Ebola virus outbreak, recruitment is less difficult. In this study, we explored the motivations of participants in two phase 1 vaccine trials that were concurrently enrolling at the same centre and compared the motivations of participants in a high-profile phase 1 Ebola vaccine trial to those in a less high-profile phase 1 adjuvanted seasonal influenza vaccine study.

Methods

An online survey which included participants’ prior experience with clinical trials, motivations to participate (including financial incentives), and demographic information was developed to examine the motivations of healthy participants in two phase 1 clinical vaccine trials conducted at the Canadian Center for Vaccinology in Halifax, Nova Scotia. Participants were invited via email to complete the online survey. Readability and clarity were assessed through pilot testing.

Results

A total of 49 (55.7%) of 88 participants of the two studies completed the survey (22 [55%] of 40 participants from the Ebola vaccine study and 27 [56.3%] of 48 from the adjuvanted influenza vaccine study). Motivations that were most frequently ranked among participants' top three in both trials were (1) wanting to contribute to the health of others, (2) wanting to participate in something important, (3) wanting to contribute to the advancement of science, and (4) wanting to receive an incentive such as money or a tablet.

Conclusions/Recommendations

Although media attention and financial compensation were more often cited by Ebola vaccine trial participants as a reason to participate, both altruistic and self-interested factors were important motivations for participants in their decision to participate in a phase 1 vaccine clinical trial.  相似文献   
10.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号